Ab­b­Vie dou­bles down on cys­tic fi­bro­sis R&D, adding a new drug to the pipeline as Ver­tex seals its dom­i­na­tion of the field with Trikaf­ta OK

Ab­b­Vie turned some heads last fall when the phar­ma gi­ant an­nounced plans to scoop up a port­fo­lio of cys­tic fi­bro­sis drugs from their part­ners at Gala­pa­gos in a $245 mil­lion deal — af­ter the lat­est da­ta came out look­ing par­tic­u­lar­ly weak com­pared to what Ver­tex was re­port­ing. Still ig­nor­ing the doubters, Ab­b­Vie is dou­bling down, bring­ing in a pre­clin­i­cal CFTR po­ten­tia­tor com­pound from the Cys­tic Fi­bro­sis Foun­da­tion to sharp­en its com­bo ap­proach.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER